Ocrevus Zunovo

(Ocrelizumab and hyaluronidase-ocsq)

Provider Order Form rev. 11/2/2024

PATIENT INFORMATION **Referral Status:** ☐ New Referral ☐ Updated Order ☐ Order Renewal

Patient Name: DOB: Patient Phone:

Patient Address: Patient Email:

Allergies: ☐ NKDA Weight (lbs/kg): Height (in/cm):

Sex: ☐ M / ☐ F Date of Last Infusion: Next Due Date: Preferred Location:

DIAGNOSIS ***(Please provide ICD-10 code in space provided)***

Multiple Sclerosis:

Other: Description:

THERAPY ADMINISTRATION & DOSING

☐ Administer Ocrevous Zunovo 920mg/23,000u subcutaneously (abdomen only) over 10 minutes once every 6 months.

☑ Monitor patient for 60mins after initial injection, subsequent injections monitor for 15 minutes.

PRE-MEDICATION ORDERS-30 minutes prior to injection

☐ Tylenol ☐500mg ☐650mg PO

☑ Benadryl ☐25mg ☐50mg PO

☑ Decadron 20mg PO

☐ Other: ________________________________

LABORATORY ORDERS

☐ CBC ☐ at each dose ☐ every: _______

☐ CMP ☐ at each dose ☐ every: _______

☐Other: ___________________________________

NURSING

☑ Hold infusion and notify provider for abnormal vital signs or signs/symptoms of active infection or recent live vaccine.

☑ Provide nursing care per Nursing Procedure, including Hypersensitivity Reaction Management Protocol and post-procedure observation

ADDITIONAL ORDERS

PROVIDER INFORMATION

Preferred Contact Name: Preferred Contact Email:

Ordering Provider: Provider NPI:

Referring Practice Name: Phone: Fax:

Practice Address: City: State: Zip Code:

REQUIRED DOCUMENTATION CHECKLIST ***(Additional documentation required for processing and insurance approval)***

Required Documentation: Patient demos, copy of front and back of primary and secondary insurance, 2 most recent OVN including treatment failures or contraindications. MRI.

Required Labs: Hepatitis B, Serum Ig levels

Provider Name *(print)* **Provider Signature** **Date**

Order valid for one year unless otherwise indicated. IV solutions/diluents may be substituted as allowed per manufacturer's instructions as necessitated by product availability.